Issued: 20 December, 2023, London UK
GSK plc Publication of Supplement to Prospectus
GSK plc today announced that the following supplement dated 20th December, 2023 to the prospectus dated 8th August, 2023 has been approved by the Financial Conduct Authority and is available for viewing:
GSK plc, GlaxoSmithKline Capital plc, GSK Capital B.V. and GSK Capital K.K. £20,000,000,000 Euro Medium Term Note Programme
Copies of the supplement to the prospectus and the document incorporated by reference within it have been submitted to the Financial Conduct Authority's National Storage Mechanism (NSM) submission portal via the Electronic Submission System (ESS) and will shortly be available for inspection at and can be downloaded from:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
For further information, please contact:
Company Secretary
GSK plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
Enquiries:
| UK Media enquiries: | Tim Foley | +44 (0) 20 8047 5502 | (London) |
| European Analyst/Investor enquiries: | Nick Stone James Dodwell | +44 7717 618 834 +44 7881 269 066 | (London) (London) |
BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENT TO THE PROSPECTUS
Please note that the information contained in the supplement to the prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the supplement to the prospectus is not addressed. Prior to relying on the information contained in the supplement to the prospectus you must ascertain from the supplement to the prospectus whether or not you are part of the intended addressees of the information contained therein.
Your right to access this service is conditional upon complying with the above
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at https://www.gsk.com/en-gb/company/.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
